Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 341Ovarian Neoplasms 177Lung Neoplasms 171Breast Neoplasms 118Fallopian Tube Neoplasms 87Neoplasms 79Carcinoma, Ovarian Epithelial 69Squamous Cell Carcinoma of Head and Neck 51Small Cell Lung Carcinoma 49Triple Negative Breast Neoplasms 41Adenocarcinoma of Lung 41Head and Neck Neoplasms 40Neoplasm Metastasis 37Neuroblastoma 34Central Nervous System Neoplasms 33Endometrial Neoplasms 28Esophageal Neoplasms 27Carcinoma 27Brain Neoplasms 27Lymphoma 26Recurrence 25Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lymphoma, Large B-Cell, Diffuse 25Urinary Bladder Neoplasms 24Adenocarcinoma, Bronchiolo-Alveolar 23Testicular Neoplasms 22Astrocytoma 22Melanoma 19Uterine Cervical Neoplasms 18Prostatic Neoplasms 18

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Metastatic Breast Cancer × Carboplatin × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡